Daniel M. Skovronsky
Chief Scientific & Product Officer and President of Lilly Research LaboratoriesDr. Daniel M. Skovronsky, also known as Dan, M.D., Ph.D., is an Independent Director of Illumina, Inc. since June 16, 2026. He was an Independent Director of Myriad Genetics, Inc. since July 22, 2020 until June 17, 2026. Dr. Skovronsky serves as Chief Scientific Officer of Loxo Oncology, Inc. He joined Eli Lilly and Company in 2010. He serves as Chief Scientific Officer at Eli Lilly and Company and served as its Chief Medical Officer until October 2023 and served as its Executive Vice President until November 2025 and served as its president of Lilly immunology since October 2023 until November 2025 and serves as its Chief product officer & President of Lilly Research Laboratories since November 2025. He had been Senior Vice President of Eli Lilly and Company since June 2018 and serves as its President of Lilly Research Laboratories since February 2020. He served as Senior VP for Science and Technology of Eli Lilly and Company and was its Chief Scientific Officer since June 2018. He was the Founder, Chief Executive Officer and President of Avid Radiopharmaceuticals Inc. Dr. Skovronsky founded Avid Radiopharmaceuticals in 2004. Prior to establishing the firm, he served as Scientific Director of High Throughput Screening and Drug Discovery at the Center for Neurodegenerative Disease Research at the University of Pennsylvania. Dr. Skovronsky served as Vice President of Radiopharmaceutical Development at Theracor Pharmaceuticals. He served as a Member of Advisory Board of Safeguard Scientifics, Inc., until October 21, 2015 and previously served as a Member of its Life Sciences Advisory Board. Dr. Skovronsky serves as a Director of Avid Radiopharmaceuticals, Inc. He has more than 20 peer-reviewed publications and two NIH-funded grants on Alzheimer’s disease research. He is the recipient of numerous scientific and business awards and was named by the Philadelphia Business Journal as one of their Forty under Forty business leaders in the region. Dr. Skovronsky received the Ernst & Young Entrepreneur of The Year 2009 Award in the Emerging Company category, which recognizes outstanding entrepreneurs who are building and leading dynamic, growing businesses. He trained as a resident in Pathology and completed a Fellowship in Neuropathology at the Hospital of the University of Pennsylvania. Dr. Skovronsky earned his M.D. from the Perelman School of Medicine, University of Pennsylvania in 2001, his Ph.D. in Neuroscience from University of Pennsylvania in 2000 and a B.S. in Molecular Biophysics and Biochemistry from Yale University in 1994.
Positions
- Company NameEli Lilly and CompanyStock CodeLLYPositionChief Scientific & Product Officer and President of Lilly Research LaboratoriesColleagues
- DADavid A. RicksChairman, President & CEO
- LELucas E. MontarceExecutive VP & CFO
- AHAnat HakimExecutive VP, General Counsel & Secretary
- JSJacob S. Van NaardenExecutive VP, President of Lilly Oncology & Head of Corporate Business Development
- STSidney TaurelChairman Emeritus
- RARalph AlvarezIndependent Director
- JRJuan Ricardo LucianoLead Independent Director
- JJJamere JacksonIndependent Director
